Cell Stem Cell reports tBE therapy remission
- Researchers published that tBE‑mediated base editing therapy produced durable clinical remission in patients with sickle cell disease and β‑thalassemia across diverse genetic backgrounds. - The study confirmed outcomes including 100% transfusion independence in transfusion‑dependent thalassaemia patients previously reported in Chinese cohorts. - The finding supports broader applicability of base‑editing therapies across populations and will shape clinical development and regulatory interest. (prnewswire.com)
1/ Cell Stem Cell published online clinical research on Sept. 7 showing CorrectSequence Therapeutics’ transformer base editor, or tBE, produced clinical remission in one sickle cell disease patient and three non-Chinese transfusion-dependent beta-thalassemia patients across different genetic backgrounds. (cell.com) 2/ The core claim is not just that the therapy worked in a small group. It is that the same editing approach appeared to work in patients from different ancestral backgrounds, extending earlier results reported in Chinese thalassemia cohorts. (cell.com) 3/ The paper, titled “Clinical base editing for β-hemoglobinopathies across different genetic backgrounds,” reported durable pan-cellular fetal hemoglobin induction, sustained elimination of vaso-occlusive crises in the sickle cell patient, and persistent transfusion independence in the thalassemia patients during follow-up. (cell.com) 4/ Mechanistically, Correctseq has said its tBE platform edits the HBG1/2 promoter region in a patient’s own hematopoietic stem cells to reactivate gamma-globin expression and raise fetal hemoglobin, or HbF. The strategy is designed to mimic naturally occurring beneficial variants rather than cut DNA with double-strand breaks. (prnewswire.com) 5/ That matters because both sickle cell disease and beta-thalassemia are beta-hemoglobinopathies. In both disorders, increasing HbF can compensate for defective adult hemoglobin: by reducing sickling in sickle cell disease and easing ineffective erythropoiesis and transfusion burden in thalassemia. (prnewswire.com) 6/ The most concrete patient-level signal in the new report is breadth, not scale. The study added one sickle cell disease patient and three transfusion-dependent thalassemia patients from outside China, with the company saying they were from Nigeria, Laos, Malaysia and Pakistan. (prnewswire.com) 7/ The sickle cell story had already been building. Correctseq said in June that the first sickle cell patient treated in China with CS-206, a tBE-based therapy, had remained free of vaso-occlusive crises for more than 15 months after engraftment, with no product-related adverse events observed to date. (prnewswire.com) 8/ The company had previously reported in August 2025 that a 21-year-old woman from Nigeria treated with its base-editing therapy remained crisis-free for six months, with HbF rising and sickle hemoglobin falling. The new Cell Stem Cell paper appears to extend that line of evidence with longer follow-up and publication in a peer-reviewed journal. (prnewswire.com) 9/ For thalassemia, the headline number the company is emphasizing is 100% transfusion independence in treated Chinese transfusion-dependent thalassemia patients, with the new paper described as confirming comparable efficacy and safety in South and Southeast Asian patients. (prnewswire.com) 10/ This does not mean the field’s scientific questions are settled. The published report is still a very small clinical dataset, and gene-editing programs in hemoglobinopathies are judged over time on durability, conditioning burden, manufacturing consistency, and long-term safety, including off-target and genomic-risk monitoring. (cell.com) 11/ It does, however, put Correctseq’s program into a more consequential category. Publication in Cell Stem Cell gives regulators, competitors and clinicians a citable dataset showing that a base-editing approach aimed at HbF reactivation may translate across populations rather than only within a single national cohort. That is an inference from the paper’s design and the company’s description of the enrolled patients. (cell.com) 12/ The next thing to watch is not rhetoric but evidence flow: additional peer-reviewed follow-up, larger cohorts, and any regulatory disclosures tied to CS-101 or CS-206. For now, the strongest verified fact is that Cell Stem Cell has published a cross-background clinical base-editing report in sickle cell disease and beta-thalassemia, with remission signals centered on HbF induction, crisis elimination and transfusion independence. (cell.com)
